Raymond James & Associates Adma Biologics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 264,392 shares of ADMA stock, worth $4.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
264,392
Previous 278,227
4.97%
Holding current value
$4.1 Million
Previous $3.11 Million
69.94%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding ADMA
# of Institutions
339Shares Held
182MCall Options Held
1.72MPut Options Held
846K-
Black Rock Inc. New York, NY18.6MShares$289 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$282 Million0.01% of portfolio
-
State Street Corp Boston, MA14.9MShares$231 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA11.3MShares$175 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.53MShares$85.9 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.05B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...